2 results
Approved WMORecruiting
Primary Part 1:-To evaluate ORR in participants treated with MK-4280A plus EV (Arm A), MK-7684A plus EV (Arm B), and pembrolizumab plus EV(Arm C) per RECIST 1.1 by BICR.- To evaluate the safety and tolerability in participants treated with MK-4280A…
Approved WMORecruiting
5. Study objective(s) and hypothesis:The aim of this study is to assess the value of early, intensive and efficient treatment of patients with recent acquired arthritis, in preventing progression into destructive RA